One Trial
Partners
  • Our Other Sites
  • care52
  • Kwikconsult
  • Caseatlas
  • Sponsor's Login
    • Call 631-897-8801
    • Text 631-897-8801
    • Email hello@1trial.com
  • View Map
  • Login or Signup

  • Login / Signup
  • Home
  • Clinical Trials

    Find Clinical Trials and Request Appointment.

  • Get Expert Help!

    Get a second opinion.

  • Get a Diagnosis
  • Annual Checkup
  • Contact Us
  • About Us
  • Terms of use
  • Privacy Policy

Search Filter Page

×
GO
Filter
close Apply Filters

Recruitment Status Reset

Study Type Reset

Patient Gender Reset

Phase Reset

Patient Age Reset

  • Home
  • Clinical Trial
  • lung cancer
    My Selections (+)
    Done Selecting
    • Edit Profile

      1. Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)

      Investigational Site Number 840043,New York,New York,United States,11201 0.64 Mile Investigational Site Number 840043,New York,New York,United States,11201

      Active, not recruitingPhase 3 NCT01146652
      Not Enrolling Do I Qualify?
    • Edit Profile

      2. A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer

      New York,New York,United States,11201 0.64 Mile New York,New York,United States,11201

      Active, not recruitingPhase 3 NCT01212991
      Not Enrolling Do I Qualify?
    • Edit Profile

      3. To Study the Healing Effect of Silver Impregnated Activated Carbon Fiber Wound Dressing on Deep Dermal Burn

      Burn Center, Department of Surgery, National Taiwan University Hospital,Taipei city,Taiwan,10002 0.83 Mile Burn Center, Department of Surgery, National Taiwan University Hospital,Taipei city,Taiwan,10002

      CompletedN/A NCT01598493
      Not Enrolling Do I Qualify?
    • Edit Profile

      4. A Prospective Randomized Trial of Efficacy of Stump Closure for Distal Pancreatectomy

      National Taiwan University Hospital,Taipei city,Taiwan,10002 0.83 Mile National Taiwan University Hospital,Taipei city,Taiwan,10002

      RecruitingN/A NCT03201653
      Contact/Enroll Do I Qualify?
    • Edit Profile

      5. Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

      Valeant Site 06,New York,New York,United States,10002 0.83 Mile Valeant Site 06,New York,New York,United States,10002

      CompletedPhase 2 NCT03003247
      Not Enrolling Do I Qualify?
    • Edit Profile

      6. New International CTEPH Database

      National Taiwan University Hospital,Taipei City,Taiwan,10002 0.83 Mile National Taiwan University Hospital,Taipei City,Taiwan,10002

      Active, not recruitingN/A NCT02656238
      Not Enrolling Do I Qualify?
    • Edit Profile

      7. Dynamic Imaging of Variation in Lupus Nephritis

      New York University School of Medicine,New York,New York,United States,10002 0.83 Mile New York University School of Medicine,New York,New York,United States,10002

      RecruitingN/A NCT03180021
      Contact/Enroll Do I Qualify?
    • Edit Profile

      8. Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)

      Novartis Investigative Site,Taipei,Taiwan,10002 1.01 Miles Novartis Investigative Site,Taipei,Taiwan,10002

      RecruitingPhase 2 NCT02435680
      Contact/Enroll Do I Qualify?
    • Edit Profile

      9. Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)

      Novartis Investigative Site,Taipei,Taiwan,10002 1.01 Miles Novartis Investigative Site,Taipei,Taiwan,10002

      CompletedPhase 2 NCT01172548
      Not Enrolling Do I Qualify?
    • Edit Profile

      10. Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

      Research Site,Taipei,Taiwan,10002 1.01 Miles Research Site,Taipei,Taiwan,10002

      Active, not recruitingPhase 3 NCT01345019
      Not Enrolling Do I Qualify?
    Show more
    Close REDO SEARCH IN THIS AREA
    Go Back & Select More
    My Selections (+) Done Selecting

    N/A

    N/A

    N/A
    Bookmark
    Share
    • Share ×
    • Click to copy to Clipboard
    This trial is recruiting.
    Contact/Enroll Do I Qualify?

    • Trial Details
    • Study Details
    • Contact/Enroll
    • Study Results
    • Reviews
    Tracking Information
    First Received Date ICMJE N/A
    Last Updated Date June 18, 2013
    Start Date November 2009
    Estimated Primary Completion Date April 2014 (final data collection date for primary outcome measure)
    Current Primary Outcome Measures ICMJE
    (submitted: November 12, 2009)

    Compared to a Usual Care control, CHESS will significantly improve lung cancer patient Quality of Life. [ Time Frame: 12-month intervention ] [ Designated as safety issue: No ]

    Compared to a Usual Care control, CHESS will significantly improve patient influence length of survival of lung cancer patient. [ Time Frame: 12-month intervention ] [ Designated as safety issue: No ]

    Original Primary Outcome Measures ICMJE Same as current
    Change History Complete list of historical versions of study NCT01012401 on ClinicalTrials.gov Archive Site
    Current Secondary Outcome Measures ICMJE
    (submitted: November 12, 2009)

    Examine the effects of CHESS use on self-determination theory (SDT) constructs. [ Time Frame: 12 mos. ] [ Designated as safety issue: No ]

    Examine the factors that moderate effect of CHESS use on self-determination theory (SDT) constructs. [ Time Frame: 12 mos. ] [ Designated as safety issue: No ]

    Examine whether these constructs mediate the effects of CHESS use on patient quality of life. [ Time Frame: 12 mos. ] [ Designated as safety issue: No ]

    Examine whether treatment participation mediates the effect patient quality of life has on survival. [ Time Frame: 12 mos/ ] [ Designated as safety issue: No ]

    Original Secondary Outcome Measures Same as current
    Current Other Outcome Measures Not Provided
    Original Other Outcome Measures Not Provided
    Descriptive Information
    Brief Title Evaluating an Interactive Cancer Communication System (ICCS) in Lung Cancer
    Official Title Interactive Cancer Communication System (ICCS) in Lung Cancer: Evaluating Survival Benefits. Center of Excellence in Cancer Communication Research: Using Technology to Enhance Cancer Communication and Improve Clinical Outcomes
    Brief Summary This study will examine the potential for an Interactive Cancer Communication System (ICCS) to impact not only psychosocial outcomes such as quality of life but also length of survival in an advanced stage lung cancer population. Two hypotheses will be tested: the Comprehensive Health Enhancement Support System- Lung Cancer (CHESS- LC) will significantly improve patient quality of life and length of overall survival as compared to a usual care control group.
    Detailed Description The prognosis for Non-Small Cell Lung Cancer patients remains poor despite recent advances in anti-cancer therapies. A lung cancer diagnosis often inflicts fear, despair, and hopelessness on patients and loved ones. For lung cancer patients in particular, a population where palliation rather than cure is often the focus, interventions addressing communication about various types of suffering are crucial to quality of life (QOL). Our Center has done extensive research testing CHESS (Comprehensive Health Enhancement Support System), a non-commercial, web-based information and support system. The recent Clinician Integration Project tested the impact of CHESS versus an Internet only Control group on QOL for caregivers of advanced stage lung cancer patients. This study yielded an unanticipated finding that CHESS may have a survival benefit for patients as one year survival was significantly increased in the CHESS group (50%) compared to Internet (34.2%). As this project did not focus on patient outcomes, follow-up with a well-formulated study designed and powered to address specific hypotheses of the nature of this effect is critical. The proposed study will specifically test QOL and survival effects of CHESS on lung cancer patients. Using sites in Wisconsin, Connecticut,Houston, and Chicago, we will randomly assign 376 advanced lung cancer patients to two study arms: a patient control group receiving Usual Care (including access to a computer and Internet) and a group given access to the CHESS website. Patients may invite a caregiver to participate. Patients will be followed for 18 months or until patient death.
    Study Type Interventional
    Study Phase Not Provided
    Study Design Allocation: Randomized
    Endpoint Classification: Efficacy Study
    Intervention Model: Parallel Assignment
    Masking: Open Label
    Primary Purpose: Supportive Care
    Condition Lung Cancer, Stage IIIb or IV
    Intervention Other: CHESS website for lung cancer patient + internet access if needed The Comprehensive Health Enhancement Support System (CHESS), a non-commercial, home-based system created by clinical, communication, and decision scientists at the University of Wisconsin, is distinguished by its quality, depth, and ease of use. It employs data on user health status to help users monitor their condition, guide them to tailored information and social support, make and implement important health decisions, and learn coping skills. Our tests and clinical trials demonstrate that an ICCS such as CHESS can be widely accepted and used, improve quality of life, information competence, and in some cases lead to more efficient use of health services. An Internet-based system, CHESS-LC integrates over 14 services to provide tailored cancer information, support, interactive tools, and communication with the clinical team.
    Study Arm (s) Experimental: CHESS with Clinician Report + Internet access
    An Internet-based system, Comprehensive Health Enhancement Support System for Lung Cancer(CHESS-LC) integrates over 14 services to provide tailored cancer information, support, and interactive tools.
    Intervention: Other: CHESS website for lung cancer patient + internet access if needed
    Adminstrative Information
    NCT Number
    Other Study ID Numbers
    Has Data Monitoring Committee
    FDA Regulated
    Responsible Party
    Study Sponsor
    Study Collaborators
    Investigators
    Information Provided By
    Verification Date

    Overall Contact:

    N/A

    Purpose:

    The purpose of the study is to determine whether ipilimumab given with paclitaxel/carboplatin has clinical benefit when compared with paclitaxel/carboplatin alone in patients with previously untreated lung cancer.

    Condition Intervention Phase
    N/A N/A N/A
    Study Type:
    Interventional
    Study Design:
    Allocation: Randomized
    Endpoint Classification: Efficacy Study
    Intervention Model: Parallel Assignment
    Masking: Open Label
    Primary Purpose: Supportive Care
    Official Title:
    Interactive Cancer Communication System (ICCS) in Lung Cancer: Evaluating Survival Benefits. Center of Excellence in Cancer Communication Research: Using Technology to Enhance Cancer Communication and Improve Clinical Outcomes
    Estimated Enrollment:
    N/A
    Listed Countries:
    N/A
    Removed Countries:
    N/A

    Eligibility :

    Minimum Age Eligible for Study:
    N/A
    Maximum Age Eligible for Study:
    N/A
    Gender Eligible for Study:
    N/A
    Accepts Healthy Volunteers:
    N/A

    Inclusion Criteria:

    Exclusion Criteria:

    Select Location to Enroll
    Choose 1 or more to contact. Also choose other trials
    Institution Location Status

    No Study Results Posted on ClinicalTrials.gov for this Study

    About Study Results Reporting on ClinicalTrials.gov

    Study Status: N/A
    Estimated Study Completion Date: April 2014
    Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
    Results First Received: N/A
    Study Type: N/A
    Study Design: N/A
    Conditions: Lung Cancer, Small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung
    Interventions: Drug: Ipilimumab
    Drug: Placebo
    Drug: Paclitaxel
    Drug: Carboplatin
    close

    Get directions on your device

    +91
    • India+91
    Send

    Google map Get Direction

    About One Trial

    • About us
    • Blog
    • Contact us
    • Developers
    • FAQ
    • How it works?
    • Privacy policy
    • Terms of use
    • Career with us

    Search by city

    • California
    • Chicago
    • Florida
    • New Jersey
    • New York
    • Philadelphia
    • San Antonio
    • Texas
    • More...

    Search by condition

    • Anal cancer
    • Acute lymphoblastic leukaemia
    • Bone cancer
    • Cancer of the mouth
    • Cervical cancer
    • Lung cancer
    • Obesity
    • Stomach cancer
    • Stomach ulcer

    Need help booking online?
    631-897-8801

    Are you a sponsor?
    Join One Trial today!

    Is something missing or incorrect?
    Help Us Improve

    Follow us  

    One Trial does not provide medical advice, diagnosis or treatment. ©Copyright 2019. All rights reserved.

    Choose One

    Send

    You are leaving the Uberdok website

    You will be subject to the terms & conditions and privacy policies of the linked site. Please review and accept at your own risk before accessing. Links on are provided solely for your convenience and do not imply an endorsement or guarantee of the accuracy of these sites. If you have any questions or concerns please contact the sites directly.

    Cancel Continue
    Message Us

    Required to be considered for the Trial

    You must meet these criteria to qualify

    These make you ineligible for participation

    Save

    Send Email To:

    Best time to call: 
       To:   
    Cancel Send

    YOUR SELECTIONS

    Specialist Change

    No SpecialistSelected

    Comments Upload Video